## There From the Beginning on DIR Advocacy



	NCPA & Member Commer	ts Congressional Letters	Stakeholder Letters	Patient/Consumer Org. Letters
'16	NCPA secures Serintroduction of DIR federal legislation	Guidance on DIR  16 SENATORS 30 REPRESENTATIVES	Support first DIR bill Sept. 99 SIGNATORIES	Asked CMS to finalize June DIR guidance 8 SIGNATORIES
'17	NCPA submits comments to CMS on DIR reporting	е	Support DIR Mar. legislation 118 SIGNATORIES	
'18	DIR Proposal  992 MEMBER COMMENTS	Support DIR Proposal Jan. 21 SENATORS 80 REPRESENTATIVES	Joint comment to DIR Proposal 120 SIGNATORIES	Support elimination Jan. of pharmacy DIR 9 SIGNATORIES
	Drug Pricing RFI  1,955 MEMBER COMMENTS	Address DIR in RFI 21 SENATORS 83 REPRESENTATIVES	Response to POTUS <b>July</b> on Drug Pricing Blueprint <b>153 SIGNATORIES</b>	
'19	DIR Proposed Rule Jar 3,493 MEMBER COMMENTS	Support DIR Proposal Mar. 29 SENATORS 62 REPRESENTATIVES	Response to DIR Jan. Proposed Rule 155 SIGNATORIES	Urged CMS to Jan. finalize DIR proposal 24 SIGNATORIES
	CMS fails to finalize Ma DIR Rule	DIR Final Rule Failure June 28 SENATORS 105 REPRESENTATIVES	Response to POTUS <b>June</b> Expressing Disappointment NCPA, NACDS, APHA, NGA NASP & FMI	
		Senate Finance Cmte Sept. urges Administration to fix DIR 23 SIGNATORIES	Drug Pricing Package July to Senate Finance 204 SIGNATORIES	
<b>'20</b>	Letter to HHS to halt DIR during PHE	NCPA letter to Mar. Congressional leaders asking for the elimination of DIR fees	JCPP Publication Apr. requesting suspension of DIR fees	
	Letter to Vice President Rair recommending an immediate suspension of DIR fees		DIKTEES	National Survey Supports
	Letter to CMS asking <b>Jul</b>	COURT FILING Filed lawsuit	t against HHS Secretary Azar for	Pharmacy-Related Part D Reforms  June 2018: NCPA commissioned Morning

NCPA Advocacy Center Meetings with Administration

repeated failure of the agency to address

DIR fees in the rulemaking process

April 2018: White House, OMB; May 2018: CMS; July 2018: HHS; Aug. 2018: HHS; Sept. 2018: White House, Domestic Policy Council; Oct. 2018: HHS, Small Business Administration; Nov. 2018: HHS, CMS, White House, OMB; Dec. 2018: HHS, White House, Political Office; Jan. 2019: White House, Domestic Policy Council; Feb. 2019: HHS; April 2019: HHS, Small Business Administration; May 2019: HHS, White House, Domestic Policy Council. CMS; July 2019: CMS; Oct. 2019: CMS; Dec. 2019: CMS, HHS April 2020: White House; June 2020: CMS; Aug. 2020: White House; Sept. 2020: CMS

June 2018: NCPA commissioned Morning
Consult national survey showed
overwhelming support for prohibiting
PBMs from charging DIR fees to
pharmacies - fees that also artificially
raise seniors' out-of-pocket costs.
Oct. 2019: A recent NCPA member
survey shows that 58% of independent
pharmacies are somewhat or very likely
to close in the next 2 years without relief
from pharmacy DIR fees. More so,
63% of respondents said that pharmacy
DIR is the number one problem facing
their pharmacy.

July

Nov.

NCPA v. Azar

Jan. '21

for inclusion of DIR reform in

Administrative actions

requesting inclusion of

DIR reform in rebate rule

advocating for inclusion of

DIR fix in final Rebate Rule

Letter to POTUS

Letter to OMB